top of page
Modern Building Geometry
GettyImages-166272432_edited_edited.jpg

ΒΙΟΓΡΑΦΙΚΟ

Ο Mauri Davide είναι ογκολόγος, Επίκουρος Καθηγητής Παθολογικής Ογκολογίας στο Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης. Έχει έδρα στο Νοσοκομείο Παπαγεωργίου και διατηρεί ιατρείο στη Θεσσαλονίκη εντός του "Ιάσειο" Πρότυπο Πολυιατρείο και στην Πρέβεζα στη Λεωφόρο Ειρήνης. Παρέχει επίσης τις υπηρεσίες του και στο Ιατρικό Διαβαλκανικό Κέντρο Θεσσαλονίκης.

Γεννήθηκε στo Merate (Como - Ιταλία). Σπούδασε Ιατρική στο Scientific Institute Hospital San Raffaele, Πανεπιστήμιο του Milano από όπου αποφοίτησε το 1995.

Έπειτα, ξεκίνησε την ειδικότητα Ουρολογίας στο Πανεπιστημιακό Νοσοκομείο San Martino της Genova (Ιταλία), όπου εργάστηκε έως το 1997. Το 1997 αποχώρησε για να τελέσει τα καθήκοντα στρατιωτικής θητείας. Το 1999 μετακινήθηκε στην Ελλάδα και το 2005 ολοκλήρωσε την ειδικότητα Παθολογικής Ογκολογίας στο  Πανεπιστημιακό Νοσοκομείο Ιωαννίνων.

Από το 2002 έως το 2010 ήταν Επιστημονικός Υπεύθυνος της PACMeR-ΠΕΔΙΕ (Πανελλήνια Ένωση Διαρκούς Ιατρικής Έρευνας) με καινοτόμο έρευνα σε μεθόδους ολιστικής αντιμετώπισης ασθενών με καρκίνο.

Το 2005 κρίθηκε άξιος να συμπεριληφθεί στην έκδοση του Who’s Who in Medicine and Healthcare (2006-2007) και την επόμενη χρονιά στην έκδοση του Who’s Who in the World (2007-2008).

Από το 2010 έως το 2014 συνεργάσθηκε με το  American College of Physicians (ACP) για το ACP PIER ON-LINE ΥΛΙΚΟ (PIER: Physicians’ Information and Education Resource) είτε ως Editorial Consultant  for module update είτε ως συγγραφέας.

Από το 2009 έως το 2017 οργάνωσε και ανέπτυξε την Μονάδα Χημειοθεραπείας του Νοσοκομείου Λαμίας. Έπειτα, μετακινήθηκε στην Ιατρική σχολή του Πανεπιστημίου Ιωαννίνων ως Επίκουρος Καθηγητής Ογκολογίας, το 2021 ανέλαβε την διεύθυνση της ίδιας Πανεπιστημιακής Κλινικής και το 2024 έγινε Αναπληρωτής Καθηγητής Ογκολογίας.

Το 2025 διορίσθηκε Επίκουρος Καθηγητής Παθολογικής Ογκολογίας στο Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης.

Έχει δημοσιεύσει περισσότερα από 170 άρθρα σε διεθνή ιατρικά περιοδικά με κριτές, με περισσότερες από 6000 αναφορές στην ιατρική βιβλιογραφία.

Ομιλία στο ASCO

2009 Ομιλία στο 45o Ετήσιο Παγκόσμιο Ογκολογικό Συνέδριο της Αμερικανικής Εταιρείας Κλινικής Ογκολογίας στο Orlando, ΗΠΑ, με θέμα
​
" Partial-Breast Irradiation Remains Investigational, But Does Not Diminish Survival"

Διεθνής Συνάντηση Εμπειρογνωμόνων

2010 

2010 Διεθνής Συνάντηση για θέσπιση κατευθυντήριων οδηγιών για τον καρκίνο. 
Biedenkopf, Γερμανία

Διεθνής Συνάντηση Εμπειρογνωμόνων 

2011

2011 Διεθνής Συνάντηση για θέσπιση κατευθυντήριων οδηγιών για τον καρκίνο. 
Biedenkopf, Γερμανία
WHO IS WHO BRIGHT.jpg

Who’s Who in Medicine and Healthcare (2006-2007)

Το 2005 συμπεριλήφθηκε στην έκδοση του Who’s Who in Medicine and Healthcare (2006-2007) και το 2006 στην έκδοση του Who’s Who in the World (2007-2008)
ΚΑΡΤΑ 1.jpg

ΛΙΣΤΑ ΔΗΜΟΣΙΕΥΣΕΩΝ

​

  1. Real-world efficacy and toxicity data of paclitaxel and ramucirumab compared with other treatment regimens in patients with advanced gastric cancer. E. Fountzilas. J. Souglakos, J. Alafis, K. Dadouli, A. Koumarianou, N. Tsoukalas, A. Nikolaidi, D. Mauri. ESMO Gastrointestinal Oncology Vol. 5 Published online: July 10, 2024

  2. TAMs and PD-1 networking in esophageal cancer: literature review. M. Yerolatsite, N. Torounidou, A. Batistatou, K. Katsanos, E. Lampri, A.-L. Amylidi, D. Mauri. ESMO Gastrointestinal OncologyVol. 7 Published online: January 23, 2025

  3. Utilizing Machine Learning for the Identification of Pre-Treatment Prognostic Non-Imaging Biomarkers of Cancer Therapy-Related Cardiac Dysfunction in Female Patients with Breast Cancer. Georga EI, Kypriadis AD, Karanasiou GS, Constantinidou A, Papakonstantinou A, Keramida K, Tsekoura D, Kampouroglou E, Cardinale DM, Mauri D, et al. Annu Int Conf IEEE Eng Med Biol Soc. 2025 Jul;2025:1-5. doi: 10.1109/EMBC58623.2025.11253200.

  4. Evaluating DDIs in cancer patients receiving anticoagulants and antineoplastics: a scoping review focusing on therapeutic efficacy and safety. Yerolatsite M, Tsoukalas N, Gerotziafas G, Pappas C, Torounidou N, Lefkou E, Mauri D, et al. Med Oncol. 2025 Oct 10;42(11):511. doi: 10.1007/s12032-025-03074-9.

  5. An Interdisciplinary Ecosystem for the Prevention of Cardiotoxicity in Older Patients With Breast Cancer: Protocol for a Prospective and Multicentric Study. Sacco GGA, Mazzocco K, Constantinidou A, Papakonstantinou A, Mauri D, et al. JMIR Res Protoc. 2025 Aug 14;14:e63455. doi: 10.2196/63455.

  6. Real-World Toxicity and Effectiveness Study of Abemaciclib in Greek Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: A Multi-Institutional Study.Fountzilas E, Aravantinou-Fatorou E, Dadouli K, Economopoulou P, Tryfonopoulos D, Vernadou A, Vorrias E, Vagionas A, Nikolaidi A, Karageorgopoulou S, Koumarianou A, Boukovinas I, Mauri D, et al. Cancers (Basel). 2025 Jul 31;17(15):2543. doi: 10.3390/cancers17152543.

  7. The role of tumor-associated macrophages and PD-1/PD-L1 networking in colorectal cancer. Yerolatsite M, Torounidou N, Amylidi AL, Zarkavelis G, Hadjigeorgiou L, Lampri E, Bali C, Georvasili V, Kampletsas E, Mauri D. Contemp Oncol (Pozn). 2025;29(2):123-130. doi: 10.5114/wo.2025.150448. Epub 2025 May 9.

  8. Impact of e-Health Interventions on Mental Health and Quality of Life in Breast Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mitsis A, Filis P, Karanasiou G, Georga EI, Mauri D, et al. Cancers (Basel). 2025 May 26;17(11):1780. doi: 10.3390/cancers17111780.

  9. Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece. Bournakis E, Bournakis A, Zolota DV, Kostouros E, Zagouri F, Papatheodoridi AP, Andrikopoulou A, Tsiatas M, Karalis K, Zakopoulou R, Mamali A, Christodoulou C, Binas I, Ardavanis A, Mauri D, et al. Expert Rev Pharmacoecon Outcomes Res. 2025 Sep;25(7):1063-1072. doi: 10.1080/14737167.2025.2505726. Epub 2025 May 23.

  10. A Prospective Study on the Role of Strain Echocardiography in Detecting Early Radiation-induced Cardiotoxicity in Left-sided Breast Cancer Patients. Gkantaifi A, Papadopoulos C, Toumpourleka M, Marketou M, Mauri D, et al. Rev Recent Clin Trials. 2025 May 8. doi: 10.2174/0115748871338729250418152731.

  11. Wound Healing Complications after Neoadjuvant Radiotherapy Combined with Targeted Therapies in Soft Tissue Sarcoma Patients. Georgopoulos NS, Tolia M, Boulouta A, Kyriazoglou A, Patriarcheas V, Dimakakos E, Schizas D, Mauri D, et al. Rev Recent Clin Trials. 2025 Mar 28. doi: 10.2174/0115748871354960250315170817.

  12. Microsatellite Stable Colorectal Tumours in Patients with Lynch Syndrome: A Case Report and Systematic Review Analysing Clinical Features and Implications for Immunotherapy. Kapoulitsa F, Mauri D, Tsilidis KK, Katsanos K, Timotheadou E, et al. K. J Gastrointest Cancer. 2025 Mar 25;56(1):86. doi: 10.1007/s12029-025-01203-1.

  13. Exploring Chemoprevention in Colorectal Cancer for Patients with Inflammatory Bowel Disease: Mechanisms of Action and Clinical Aspects. Fousekis FS, Mpakogiannis K, Filis P, Skamnelos A, Christodoulou DK, Mauri D, Katsanos KH. Cancers (Basel). 2025 Jan 12;17(2):229. doi: 10.3390/cancers17020229.

  14. Grading the evidence for physical activity and any outcome in cancer survivors: An Umbrella review of 740 meta-analytic associations. Filis P, Markozannes G, Chan DS, Mauri D, Foukakis T, et al. Crit Rev Oncol Hematol. 2025 Mar;207:104602. doi: 10.1016/j.critrevonc.2024.104602. Epub 2024 Dec 25.

  15. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.

  16. Digital ischemia: a rare immune-related adverse event of immune checkpoint inhibitors-case report and review of the literature. Yerolatsite M, Torounidou N, Venetsanopoulou AI, Zarkavelis G, Mauri D, Voulgari PV. Rheumatol Int. 2024 Dec;44(12):3141-3149. doi: 10.1007/s00296-024-05709-y. Epub 2024 Sep 4.

  17. Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT Study. Liontos M, Bournakis E, Bournakis A, Kostouros E, Zolota V, Papatheodoridi AP, Karalis K, Kyriazoglou A, Zakopoulou R, Vasili E, Tzovaras A, Dimitriadis I, Emmanouil G, Mauri D, et al. Clin Genitourin Cancer. 2024 Dec;22(6):102170. doi: 10.1016/j.clgc.2024.102170. Epub 2024 Jul 26.

  18. Exploring RAS mutation incidence and temporal heterogeneity in metastatic colorectal cancer patients - a single-institution experience utilising circulating tumour DNA. Zarkavelis G, Amylidi AL, Torounidou N, Yerolatsite M, Keravasili A, Keramisanou V, Mauri D. Contemp Oncol (Pozn). 2024;28(1):45-50. doi: 10.5114/wo.2024.138899. Epub 2024 Apr 17.

  19. Treatment sequencing in metastatic colorectal cancer.Torounidou N, Yerolatsite M, Zarkavelis G, Amylidi AL, Karafousia V, Kampletsas E, Mauri D. Contemp Oncol (Pozn). 2024;28(4):283-290. doi: 10.5114/wo.2024.146982. Epub 2025 Jan 15.

  20. Longitudinal Muscle Biopsies Reveal Inter- and Intra-Subject Variability in Cancer Cachexia: Paving the Way for Biopsy-Guided Tailored Treatment. Filis P, Tzavellas NP, Stagikas D, Zachariou C, Lekkas P, Kosmas D, Dounousi E, Sarmas I, Ntzani E, Mauri D., et al. Cancers. 2024; 16(5):1075.

  21. Exploring Immune-Related Adverse Events: A Case of Febrile Neutropenia in a Melanoma Patient Receiving Immunotherapy. Yerolatsite M, Torounidou N, Amylidi AL, Kapoulitsa F, Kampletsas E, Zarkavelis G, Mauri D. Case Rep Oncol. 2024 Mar 4;17(1):417-422. doi: 10.1159/000536288.

  22. TAMs and PD-1 Networking in Gastric Cancer: A Review of the Literature. Yerolatsite M, Torounidou N, Gogadis A, Kapoulitsa F, Ntellas P, Lampri E, Tolia M, Batistatou A, Katsanos K, Mauri D.  Cancers (Basel). 2023 Dec 30;16(1):196. doi: 10.3390/cancers16010196.

  23. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes. Dimitrakopoulos FI, Goussia A, Koliou GA, Dadouli K, Batistatou A, Kourea HP, Bobos M, Arapantoni-Dadioti P, Tzaida O, Koletsa T, Chrisafi S, Sotiropoulou M, Papoudou-Bai A, Nicolaou I, Charchanti A, Mauri D, et al.  Breast. 2023 Dec 25;73:103668. doi: 10.1016/j.breast.2023.103668.

  24. Exploring a Rarity: Incidence of and Therapeutic Approaches for Neurological Complications and Hypophysitis in Cancer Patients on Immune Checkpoint Inhibitors-A Single-Center Study.Amylidi AL, Gogadis A, Yerolatsite M, Zarkavelis G, Torounidou N, Keramisanou V, Kampletsas E, Mauri D. Curr Oncol. 2023 Dec 18;30(12):10509-10518. doi: 10.3390/curroncol30120766.

  25. Risk Stratification for Cardiotoxicity in Breast Cancer Patients:Predicting Early Decline of LVEF After Treatment. Kostas M. Tsiouris, Alexandros Mitsis, Grigoris Grigoriadis, Georgia Karanasiou, Lampros Lakkas, Davide Mauri, et al. IEEE EMBC 2023

  26. CARDIOCARE: An integrated platform for the management of elderly multimorbid patients with breast cancer therapy induced cardiac toxicity. G. Karanasiou, L. Koumakis, S. Sfakianakis, G. Manikis, G. Kalliatakis, A. Antoniades, L. Lakkas, D.Mauri, et al, IEEE, 2023

  27. Concordance between three homologous recombination deficiency (HRD) assays in patients with high-grade epithelial ovarian cancer. Elena Fountzilas, Kyriaki Papadopoulou, Thomas Chatzikonstantinou, Georgios Karakatsoulis, Pantelis Constantoulakis, Aikaterini Tsantikidi, Georgios Tsaousis, Sofia Karageorgopoulou, Anna Koumarianou, Davide Mauri, et al. Cancers (Basel). 2023 Nov 22;15(23):5525. doi: 10.3390/cancers15235525.

  28. New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review. et al. Cancers (Basel). 2023 Jun 22;15(13):3290. doi: 10.3390/cancers15133290.

  29. Circulating Tumor DNA in the Management of Early-Stage Breast Cancer. Vlataki K, Antonouli S, Kalyvioti C, Lampri E, Kamina S, Mauri D., Harissis HV, Magklara A. Cells. 2023 Jun 7;12(12):1573. doi: 10.3390/cells12121573.

  30. Real-world Data and Economic Evaluation of Nivolumab in Previously Treated Non-small Cell Lung Cancer Greek Patients. Linardou H, Lampaki S, Koliou GA, Vozikis A, Boutis A, Nikolaidi A, Kontogiorgos I, Papakotoulas P, Christopoulou A, Spyratos D, Bafaloukos D, Psyrri A, Grivas A, Koumarianou A, Tsiakitzis K, Mauri D., et al. Anticancer Res. 2023 Jun;43(6):2799-2812. doi: 10.21873/anticanres.16449.

  31. The Role of Preoperative Chemotherapy in the Management of Synchronous Resectable Colorectal Liver Metastases: A Meta-Analysis. Tepelenis K, Pappas-Gogos G, Ntellas P, Tsimogiannis K, Dadouli K, Mauri D., Glantzounis GK. Curr Oncol. 2023 Apr 25;30(5):4499-4511. doi: 10.3390/curroncol30050340.

  32. Metformin: A Promising Radiosensitizer in Neoadjuvant Rectal Cancer Treatment.Georgopoulos NS, Tolia M, Mauri D., Kamposioras K, Charalampakis N, Tsoukalas N, Gkantaifi Α. Rev Recent Clin Trials. 2023;18(3):172-180. doi: 10.2174/1574887118666230428114349.

  33. Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role? Sgouros J, Gkoura S, Spathas N, Tzoudas F, Karampinos K, Miaris N, Visvikis A, Dessypris N, Mauri D., et al. Clin Colorectal Cancer. 2023 Jun;22(2):238-244. doi: 10.1016/j.clcc.2023.02.007. Epub 2023 Mar 4.

  34. Superficial soft tissue sarcomas: 10‑year survival outcomes. Tolia M, Gkantaifi A, Hayward L, Gupta G, Kyriazoglou A, Mauri D. Nixon I. Oncol Lett. 2023 Jan 27;25(3):96. doi: 10.3892/ol.2023.13682. eCollection 2023 Mar.

  35. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry.Mountzios G, Planchard D, Metro G, Tsiouda D, Prelaj A, Lampaki S, Shalata W, Riudavets M, Christopoulos P, Girard N, Albarrán-Artahona V, Garcia Campelo R, Samitas K, Banna GL, Boukovinas I, Agbarya A, Koumarianou A, Perdikouri EI, Kosmidis P, Linardou H, Mauri D., et al. JTO Clin Res Rep. 2022 Nov 20;4(1):100433. doi: 10.1016/j.jtocrr.2022.100433. eCollection 2023 Jan.

  36. COVID-19 Emotional and Mental Impact on Cancer Patients Receiving Radiotherapy: An Interpretation of Potential Explaining Descriptors. Tolia M, Symvoulakis EK, Matalliotakis E, Kamekis A, Adamou M, Kountourakis P, Mauri D., Dakanalis A, Alexidis P, Varveris A, Antoniadis C, Matthaios D, Paraskeva M, Giaginis C, Kamposioras K. Curr Oncol. 2023 Jan 1;30(1):586-597. doi: 10.3390/curroncol30010046.

  37. Hyperthermic intraperitoneal chemotherapy for management of gastrointestinal and biliary tract malignancies: a systematic review and meta-analysis of randomized trials. Filis P, Kanellopoulou A, Gogadis A, Filis N, Kamposioras K, Kapoulitsa F, Mauri D. Ann Gastroenterol. 2023 Jan-Feb;36(1):87-96. doi: 10.20524/aog.2023.0758. Epub 2022 Nov 15.

  38. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: a systematic review and meta-analysis of randomized trials. Filis P, Mauri D., Markozannes G, Tolia M, Filis N, Tsilidis K. ESMO Open. 2022 Oct;7(5):100586. doi: 10.1016/j.esmoop.2022.100586. Epub 2022 Sep 16.

  39. Interior Design: A New Perspective in Supportive Care of Patients with Acute Onset of Debilitating Diseases. Mauri D., Kampletsas E, Smyris G, Tsali L, Tsekeris P, Harissis H, Kamposioras K, Tolia M, Hyphantis T, Ntellas P, Gazouli I, Zarkavelis G, Mavroeidis L, Amylidi AL, Torounidou N, Gogadis A, Nixon J. Palliat Med Rep. 2021 Dec 27;2(1):365-368. doi: 10.1089/pmr.2021.0031. eCollection 2021.

  40. Cancer patient care during different war times; is the response too slow? Tolia M, Kamposioras K, Symvoulakis EK, Mauri D., Skouras P, Schizas D, Charalampakis N, Kokakis I, Matthaios D, Gazouli I, Ferentinos K, Girvalaki C, Apostolidis K. ESMO Open. 2022 Aug;7(4):100557. doi: 10.1016/j.esmoop.2022.100557. Epub 2022 Aug 11.

  41. Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. Zagouri F, Koliou GA, Dimitrakopoulos F, Papadimitriou C, Binas I, Koutras A, Papakostas P, Markopoulos C, Venizelos V, Xepapadakis G, AndrikopoulouΑ, Karanikiotis C, Psyrri A, Bafaloukos D, Kosmidis P, Aravantinos G, Res E, Mauri D., et al. Br J Cancer. 2022 Sep;127(4):695-703. doi: 10.1038/s41416-022-01846-y. Epub 2022 May 24.

  42. Gastric metastasis from breast cancer presenting as dysphagia. Fousekis FS, Tepelenis K, Stefanou SK, Stefanou CK, Pappas-Gogos G, Theopistos V, Evangelou Z, Mauri D., Christodoulou DK. J Surg Case Rep. 2022 Mar 17;2022(3):rjac080. doi: 10.1093/jscr/rjac080. eCollection 2022 Mar.

  43. Radiotherapy and Breast Reconstruction: What Is the Ideal Timing? A Narrative Review. Letsiou E, Tsakatikas S, Vakis G, Tsapakidis K, Charalampakis N, Diamantis A, Poultsidi A, Michelakis D, de Bree E, Mauri D., Tsoukalas N, Antoniades C, Tolia M. Rev Recent Clin Trials.2022;17(2):73-85.doi: 10.2174/1574887117666220314161609.

  44. Next-Generation Sequencing of Circulating Tumor DNA Can Optimize Second-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer after Progression on anti-EGFR Therapy: Time to Rethink Our Approach.Mauri D., Kamposioras K, Matthaios D, Tolia M, Nixon I et al., Oncol Res Treat. 2022;45(4):216-221. doi: 10.1159/000521845. Epub 2022 Jan 9.

  45. COVID-19 Vaccinations: Summary Guidance for Cancer Patients in 28 Languages: Breaking Barriers to Cancer Patient Information. Mauri D., Kamposioras K, Tsali L, Dambrosio M, De Bari B, et al. Rev Recent Clin Trials. 2022;17(1):11-14. doi: 10.2174/1574887116666211028145848.

  46. YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango. Matthaios D, Tolia M, Mauri D., Kamposioras K, Karamouzis M. Biomedicines. 2021 Dec 20;9(12):1949. doi: 10.3390/biomedicines9121949.

  47. Immunotherapy Efficacy in the Initial Lines of Treatment in Advanced Upper Gastrointestinal Malignancies: A Systematic Review of the Literature. Kamposioras K, Ntellas P, Nikolaou M, Germetaki T, Gazouli I, Dadouli K, Zarkavelis G, Amylidi AL, Tolia M, Mauri D.  JNCI Cancer Spectr. 2021 Nov 16;5(6):pkab088. doi: 10.1093/jncics/pkab088. eCollection 2021 Dec.

  48. Prognostic significance and therapeutic implications of Caveolin-1 in gastrointestinal tract malignancies. Kamposioras K, Vassilakopoulou M, Anthoney A, Bariuoso J, Mauri D., Mansoor W, Papadopoulos V, Dimas K. Pharmacol Ther. 2022 May;233:108028. doi: 10.1016/j.pharmthera.2021.108028. Epub 2021 Oct 29..

  49. The prognostic and predictive impact of low estrogen receptor expression in early breast cancer: a systematic review and meta-analysis. Paakkola NM, Karakatsanis A, Mauri D., Foukakis T, Valachis A. ESMO Open. 2021 Dec;6(6):100289. doi: 10.1016/j.esmoop.2021.100289. Epub 2021 Oct 19.

  50. Plasma ctDNA RAS status selects patients for anti-EGFR treatment rechallenge in metastatic colorectal cancer: a meta-analysis. Vlachou MS, Mauri D., Zarkavelis G, Ntellas P, Tagkas C, Gkoura S, Pentheroudakis G. Exp Oncol. 2021 Sep;43(3):252-256. doi: 10.32471/exp-oncology.2312-8852.vol-43-no-3.16592.

  51. Advanced germ cell tumors and chemotherapy in G6PD deficient patients: Yes to chemotherapy but no to rasburicase and some premedications.Gazouli I, Baltogiannis D, Ntellas P, Smaragdi Vlachou M, Tagkas C, Champilomatis I, Kampletsas Ε, Tolia M, Mauri D. J BUON. 2021 Jul-Aug;26(4):1642-1646.

  52. Is there a role for Gallium-67 SPECT in distinguishing progression and pseudoprogresion in oncologic patients receiving immunotherapy? Mauri D., Tsiouris S, Gkoura S, Gazouli I, Ntellas P, Amylidis A, Kampletsas L, Fotopoulos A. Cancer Treat Res Commun. 2021;28:100441. doi: 10.1016/j.ctarc.2021.100441. Epub 2021 Aug 8.

  53. Cutaneous soft tissue sarcomas: survival-related factors. Gkantaifi A, Diamantis A, Mauri D., Nixon I, Kyriazoglou A, Baloyiannis I, Tsoukalas N, Charalampakis N, Schizas D, Cuccia F, Alongi F, de Mello RA, Iliadis G, Kamposioras K, Mazonakis M, Tolia M. Arch Dermatol Res. 2022 Sep;314(7):625-631. doi: 10.1007/s00403-021-02268-1. Epub 2021 Jul 17.

  54. Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough? Fountzilas E, Kotoula V, Koliou GA, Liontos M, Papadopoulou K, Giannoulatou E, Papanikolaou A, Tikas I, Chrisafi S, Mauri D., et al.. Front Oncol. 2021 Jun 1;11:683057. doi: 10.3389/fonc.2021.683057. eCollection 2021.

  55. AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study. Zarkavelis G, Samantas E, Koliou GA, Papadopoulou K, Mauri D., et al. Acta Oncol. 2021 Jun;60(6):785-793. doi: 10.1080/0284186X.2021.1912822. Epub 2021 May 18.

  56. Inmate cancer patients–highlighting the importance of a holistic approach to oncological care. Tolia, Maria, Emmanouil K. Symvoulakis, Konstantinos Kamposioras, Davide Mauri, Angeliki Skoutari, Panagiotis Volkos, Dimitrios Schizas et al. Journal of BUON 26, no. 6 (2021): 2688-2703.

  57. Ureteral carcinoma metastasizing to the testicle: Can misdiagnosis of orchiepididymitis be avoided?Gazouli I, Tsampalas S, Tsimaris I, Zarkavelis G, Grivas N, Kampletsas E, Papadaki A, Mavroeidis L, Ntellas P, Gkoura S, Tsali L, Amylidi AL, Vlachou MS, Mauri D. Urol Ann. 2021 Jan-Mar;13(1):86-88. doi: 10.4103/UA.UA_124_20. Epub 2021 Jan 19.

  58. Chemotherapy associated ovarian failure. Davide Mauri, Ioanna Gazouli, Georgios Zarkavelis, Alexandra Papadaki, Leonidas Mavroeidis, Stefania Gkoura, Panagiotis Ntellas, Anna-Lea Amylidi, Lampriani Tsali, Eleftherios Kampletsas. Front. Endocrinol., 08 December 2020, https://doi.org/10.3389/fendo.2020.572388

  59. Synthesis of recommendations from 25 countries and 31 Oncology societies: How to navigate through covid-19 labyrinth. Konstantinos Kamposioras, Davide Mauri, Konstantinos Papadimitriou, Alan Anthoney, Nadia Hindi, Branka Petricevic, et al. Front. Oncol., 19 November 2020, https://doi.org/10.3389/fonc.2020.575148

  60. Predictive role of HER2-status on the effectiveness of endocrine adjuvant treatment in postmenopausal breast cancer patients: a population-based cohort study. Schiza A, Mauri D., Fredriksson I, Anna-Karin Wennstig, Valachis A. Breast Cancer Res Treat. 2020 Nov 30. doi: 10.1007/s10549-020-06022-5.

  61. Old Player-New Tricks: Non Angiogenic Effects of the VEGF/VEGFR Pathway in Cancer. Ntellas P, Mavroeidis L, Gkoura S, Gazouli I, Amylidi AL, Papadaki A, Zarkavelis G, Mauri D., Karpathiou G, Kolettas E, Batistatou A, Pentheroudakis G. Cancers (Basel). 2020 Oct 27;12(11):3145. doi: 10.3390/cancers12113145.

  62. Interior design in cancer care: simple structural solutions in storey houses improve patients’ quality of life, mood and performance. Davide Mauri, Lampriani Tsali, Georgios Zarkavelis, Athanasios Soukovelos, Diamantina Lymperatou, Alexandra Papadaki, Panagiotis Ntellas, Stefania Gkoura, Ioanna Mouzaki, Eleftherios Kampletsas. J BUON 2020, pp 1673-167

  63. Radiation Induced Oral Mucositis in Head and Neck Cancer Patients. Is There Any Effective Management? Review of the Literature of the Last Five Years. Areti Gkantaifi, Emmanouil Vardas, Filippo Alongi, Nikolaos Tsoukalas, Haytham Hamed Saraireh, Nikolaos Charalampakis, LöveyJozsef, JiannisHajiioannou, EfthymiosKyrodimos, Konstantinos Tsanadis, Mauri Davide, Christopoulos Christos, George Iliadis, Maria Tolia. "Reviews on Recent Clinical Trials 2020 DOI: 10.2174/1574887115666200731182708

  64. Behind the numbers and the panic of a viral pandemic: fixed restrictive oncology guidance may jeopardize patients' survival. Mauri D., Tzachanis D, Valachis A, et al. K. J BUON. 2020 May-Jun;25(3):1277-1280

  65. Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncology Group. Fountzilas E, Koliou GA, Vozikis A, Rapti V, Nikolakopoulos A, Boutis A,Christopoulou A, Kontogiorgos I, Karageorgopoulou S, Lalla E, Tryfonopoulos D, Boukovinas I, Rapti C, Nikolaidi A, Karteri S, Moirogiorgou E, Binas I, Mauri D., et al. ESMO Open. 2020 Aug;5(4):e000774. doi:10.1136/esmoopen-2020-000774.

  66. Honey against radiation induced oral mucositis in head and neck cancer patients. An Umbrella Review of Systematic Reviews and Meta-Analyses of the literature. Gkantaifi A, Alongi F, Vardas E, Cuccia F, Hajiioannou J, Kyrodimos E, Christopoulos C, Mauri D., Charalampakis N, Trogkanis N, Tsoukalas N, Iliadis G, Tolia M. Rev Recent Clin Trials. 2020 Jul 9. doi:10.2174/1574887115666200709140405. Epub ahead of print.  

  67. The cancer immunotherapy environment may confound the utility of anti-TIF-1γ in differentiating between paraneoplastic and treatment-related dermatomyositis. Report of a case and review of the literature. Zarkavelis G, Mauri D., Karassa F, Eleftherios K, Pentheroudakis G, Pappadaki A, Mavroeidis L, Ntellas P, Gkoura S, Gazouli I. Contemp Oncol (Pozn). 2020;24(1):75-78. doi:10.5114/wo.2020.94727. Epub 2020 Mar 30.

  68. Metabolic consequences of immune checkpoint inhibitors: A new challenge in clinical practice. Parthymos I, Liamis G, Dounousi E, Pentheroudakis G, Mauri D., Zarkavelis G, Florentin M. Crit Rev Oncol Hematol. 2020 Jul;151:102979. doi: 10.1016/j.critrevonc.2020.102979. Epub 2020 May 7.

  69. International Oncology Panel and European Cancer Patient Coalition collaborators. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic. Mauri D., Kamposioras K, Tolia M, Alongi F, Tzachanis D. Lancet Oncol. 2020 Jun;21(6):759-760. doi:10.1016/S1470-2045(20)30278-3. Epub 2020 May 13.

  70. Patient and family support in the era of fake-medicine: food for thought from an international consensus panel. Mauri D., Kamposioras K, Tzachanis D, Tolia M, Valachis A, et al. ESMO Open. 2020 Apr;5(2):e000696. doi: 10.1136/esmoopen-2020-000696.

  71. Observational Study of Clinical Practice in Patients with Pancreatic Adenocarcinoma in Greece. George Papaxoinis, Athanasios Athanasiadis, Joseph Sgouros, Anastastios Visvikis, Maria Drizou, Emmanouil Kontopodis, Anna Koumarianou, Suzana Stojanovska, Gerasimos Aravantinos, Ippokratis Korantzis, Alexandros Ioannou, Ioannis Varthalitis, Dimitrios Doufexis, Michail Nikolaou, Georgios Lypas, Iliada Bompolaki, Athina Christopoulou, Michael Liontos, Nikolaos Tsoukalas, Davide Mauri, et al.  Journal of Oncology, vol. 2020, Article ID 5304516.

  72. Rauth S, Mavroeidis L, Ntellas P, Gazouli I, Gkoura S, Papadaki A, Mauri D., Metaxas I, Douillard JY, Pentheroudakis G.  Old Drug, new clinical use, no man’s land for the indication: an awareness call from European experts. ESMO Open. 2020;5.

  73. Cancer pain… who cares? International and national patterns of evidence-based global guidelines recommendations for physicians on the Web (2011 vs. 2018). Mauri D., Kalopita K, Tsali L, P Polyzos N, Valachis A, et al. JBUON. 2020 Jan-Feb;25(1):62-73.

  74. Mismatch repair deficiency/microsatellite instability testing as predictive immunotherapy biomarkers-possible diagnostic missteps trusting a single method. Gazouli I, Zarkavelis G, Mauri D., Pentheroudakis G. Ann Transl Med. 2019 Dec;7(Suppl 8):S329. doi: 10.21037/atm.2019.09.144.

  75. Politi A, Angelos D, Mauri D., Zarkavelis G, Pentheroudakis G. A case report of psoriasis flare following immunotherapy: Report of an important entity and literature review. SAGE Open Med Case Rep. 2020 Jan 13;8:2050313X19897707. doi:10.1177/2050313X19897707.

  76. Mauri D.,Tsali L, P Polyzos N, Valachis A, Zafeiri G, Kalopita K, Tsiara A, Yerolatsite M, Zarkavelis G, Kampletsas E, Mouzaki I, Ntellas P, Filis P, Pentheroudakis G. Facing internet fake-medicine and web para-pharmacy in the total absence of official recommendations from medical societies. J BUON. 2019 Jul-Aug;24(4):1314-1325.

  77. Angiogenic and Antiangiogenic VEGFA Splice Variants in Colorectal Cancer: Prospective Retrospective Cohort Study in Patients Treated With Irinotecan-Based Chemotherapy and Bevacizumab. Pentheroudakis G, Mavroeidis L, Papadopoulou K, Koliou GA, Bamia C, Chatzopoulos K, Samantas E, Mauri D., et al. Clin Colorectal Cancer. 2019 Dec;18(4):e370-e384. doi: 10.1016/j.clcc.2019.07.007. Epub 2019 Jul 15.

  78. Global coverage and consistency of guideline recommendations for cancer cachexia on the Web in 2011 and 2018. Mauri D., Zafeiri G, Yerolatsite M, Tsali L, Zarkavelis G, Tsiara A, Polyzos NP, Valachis A, Kalopita K, Kampletsas E, Papadaki A, Peponi E, Kapoulitsa F, Filis P, Pentheroudakis G. Contemp Oncol (Pozn). 2019;23(2):100-109. doi: 10.5114/wo.2019.85882. Epub 2019 Jun 13. PMID:31316293;

  79. How I treat cancers of unknown primary. Zarkavelis G, Mauri D., Pentheroudakis G. ESMO Open. 2019 May 10;4(Suppl 2):e000502. doi:10.1136/esmoopen-2019-000502.

  80. Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal Cancer. Rallis G, Koletsa T, Saridaki Z, Manousou K, Koliou GA, Kostopoulos I, Kotoula V, Makatsoris T, Kourea HP, Raptou G, Chrisafi S, Samantas E, Papaparaskeva K, Pazarli E, Papakostas P, Kafiri G, Mauri D., et al. Anticancer Res. 2019 Apr;39(4):2129-2138. doi:10.21873/anticanres.13326.

  81. Microvessel Density and Impact of Angiogenesis on Survival of Resected Pancreatic Cancer Patients: A Systematic Review and Meta-analysis. Ntellas P, Dadouli K, Perivoliotis K, Sogka E, Pentheroudakis G, Ioannou M, Hadjichristodoulou C, Tepetes K, Mauri D. Pancreas. 2019 Feb;48(2):233-241. doi:10.1097/MPA.0000000000001237.

  82. Identification of catheter misplacement in early port CVCdysfunction. Mauri D., Zafeiri G, Tsali L, Chalkidou A, Zarkavelis G, Papadaki A, Filis P, Pentheroudakis G. Contemp Oncol (Pozn). 2018;22(2):129-134. doi:10.5114/wo.2018.77044. Epub 2018 Jun 30.

  83. Postoperative chemotherapy with single-agent Fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials. Mauri D., Zarkavelis G, Filis P, Tsali L, Zafeiri G, Papadaki A, Vassou A, Georgopoulos C, Pentheroudakis G. ESMO Open. 2018 Jun 23;3(4):e000343. doi:10.1136/esmoopen-2018-000343.

  84. Role of chemotherapy in resectable liver metastases from colorectal cancer: food for thought from pooled evidence. Mauri D.,Filis P, Tsali L, Zarkavelis G, Pentheroudakis G. ESMO Open. 2018 Jun 19;3(4):e000367. doi:10.1136/esmoopen-2018-000367.

  85. Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. Fostira F, Saloustros E, Apostolou P, Vagena A, Kalfakakou D, Mauri D.,Tryfonopoulos D, Georgoulias V, Yannoukakos D, Fountzilas G, Konstantopoulou I. Breast Cancer Res Treat.2018 May;169(1):105-113. doi:10.1007/s10549-018-4661-x. Epub 2018 Jan 15.

  86. Cancer Cachexia: global awareness and guideline implementation on the web. Mauri D., Tsiara A, Valachis A, Kalopita K, Tsali L, Tolis P, Polyzos NP. BMJ supp & pall care2013 Jun;3(2):155-60.

  87. Cancer Pain: global awareness and guideline implementation. Mauri D., Kalopita K, Tsiara A, Valachis A, Tsali L, Papadimitriou L, Xanthos T, Panagou P, Panagiotakis C, Kalopita S,Polyzos NP. Forum Clin Oncol 2013;4(3):19-31.

  88. Breakthrough  in research and treatment of early breast cancer: an overview of the last three decades (International bord of experts) Kaufmann M, von Minckwitz G, Bergh J, Conte Pf, Darby S, Eiermann W, Howell A, Kiechle M, Mauri D., Senn HJ, Viale G, Loibl S. Arch Gynecol Obstet. 2013;288(6):1203-12

  89. What do European Community oncology expects from European Society for Medical Oncology. Result from a survey among community oncologists in Germany, Greece, Hungary, Italy, Luxembourg, Romania, and Spain Eckert R, Curca R, D'Addario G, Lanzetta G, Martorell PM, Mauri D., Rauh S, Schmitz S, Tamas K, Karamouzis MV. Ann Oncol 2013 May;24(5):1419-20​

  90. Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Valachis Α, Polyzos NP, Coleman RE, Gnant M, Eidtmann H, Brufsky AM, Aft R, Tevaanwerk AJ, Swenson K,  Lind P, Mauri D. Oncologist 2013; 18(4):353-61

  91. Reply to HJ. Valachis Α, Polyzos NP, Nearchou A, Lind P, Mauri D. Conter. J Clin Oncol. 2012;30(31):3895

  92. Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: a meta-analysis of randomized evidence. Valachis Α, Nearchou A, Lind P, Mauri D. Breast Cancer Res Treat. 2012; 35(3):655-62. 

  93. Valachis Α, Polyzos NP, Nearchou A, Lind P, Mauri D. Finantial relationships in economic analyses of targeted therapies in oncology. J Clin Oncol. 2012;30(12):1316-20

  94. Recommendation from an international consensus conference on the current status and the future of neoadjuvant systemic therapy in primary breast cancer. Kauffman M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M,  Denkert C, Eiermann W, Gnant M, Harris JR, Karn T, Liedtke C, Mauri D., Rouzier R, Ruckhaeberle E, Semiglazov V, Symmans WF, Tutt A, Pustzai L.  Ann Surg Oncol. 2012;19(5):1508-1516.

  95. Recurrent multiloculated symptomatic malignant pleural effusion after talk pleurodesis: drain and re-drain improve quality of life and patient survival. Tsiara A, Tsali L, Valachis A, Nearchou A, Panagopoulos A, Koutsianas D, Manos E, Mauri D. Forum Clin Oncol 2011;2(5).

  96. Translational medicine and reliability of single-nucleotide polymorphism studies: can we believe in SNP reports or not? Valachis A, Mauri D., Neophytou C, Polyzos NP, Tsali L, Garras A, Papanikoloaou EG. Int J Med Sci 2011;8(6):492-500

  97. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: A systematic review and meta-analysis. Valachis A, Mauri D., Polyzos NP, Chlouverakis G, Mavroudis D, Georgoulias V. Breast. 2011 Jul 22.

  98. Guidelines on chemotherapy in advanced stage gynecological malignancies: an evaluation of 224 professional societies and organizations. Polyzos NP, Mauri D., Ioannidis JP. PLoS One. 2011;6(5):e20106. Epub 2011 May 17

  99. Safety of Pregnancy After Primary Breast Carcinoma in Young Women: A Meta-Analysis to Overcome Bias of Healthy Mother Effect Studies. Valachis A, Tsali L, Pesce LL, Polyzos NP, Dimitriadis C, Tsalis K, Mauri D. Obstet Gynecol Surv. 2010 Dec;65(12):786-793

  100. Industry involvement in the assumptions of cost-effectiveness analysis: the diagnostic accuracy of the Pap test. Polyzos NP, Valachis A, Mauri D., Ioannidis JPA. CMAJ 2011;183(6):E337-43

  101. Obstetric outcomes after treatment of periodontal disease during pregnancy: systematic review and meta-analysis. Polyzos NP, Polyzos IP, Zavos A, Valachis A, Mauri D., Papanikolaou EG, Tzioras S, Weber D, Messinis IE. BMJ. 2010 Dec 29;341:c7017. doi: 10.1136/bmj.c7017. Review.

  102. Cervical cancer assessment in Romania under EUROCHIP-2. Apostol I, Baban A, Nicula F, Suteu O, Coza D, Amati C, Baili P. EUROCHIP Working Group. (Oberaigner W, Van Eycken E, Sundseth H, Arbyn M, Valerianova Z, Zlatkov V, Kostova P, Panayotova Y, Holub J, Pavlou P, Papageorgiou C, Von Euler M, Veerus P, Sankila R, Anttila A, Holli K, Grosclaude P, Danzon A, Tzala L, Kamposioras KV, Ferentinos G, Mauri D., et al.) Tumori. 2010 Jul-Aug;96(4):545-52

  103. Cervical cancer screening in Bulgaria--past and present experience. Valerianova Z, Panayotova Y, Amati C, Baili P; EUROCHIP Working Group (Oberaigner W, Van Eycken E, Sundseth H, Arbyn M, Valerianova Z, Zlatkov V, Kostova P, Panayotova Y, Vasiliev N, Holub J, Pavlou P, Papageorgiou C, Von Euler M, Veerus P, Sankila R, Anttila A, Holli K, Grosclaude P, Danzon A, Tzala L, Kamposioras KV, Ferentinos G, Mauri D., et al ). Tumori. 2010 Jul-Aug;96(4):538-44

  104. Past, present and future of the cervical cancer screening in Latvia. Viberga I, Engele L, Baili P. EUROCHIP Working Group (Oberaigner W, Van Eycken E, Sundseth H, Arbyn M, Valerianova Z, Zlatkov V, Kostova P, Panayotova Y, Holub J, Pavlou P, Papageorgiou C, Von Euler M, Veerus P, Sankila R, Anttila A, Holli K, Grosclaude P, Danzon A, Tzala L, Kamposioras KV, Ferentinos G, Mauri D., et al.) Tumori. 2010 Jul-Aug;96(4):529-37

  105. Impact of implementing a nationwide cervical cancer screening program on female population coverage by Pap-tests in Estonia. Veerus P, Arbyn M, Amati C, Paolo B. EUROCHIP Working Group (Oberaigner W, Van Eycken E, Sundseth H, Arbyn M, Valerianova Z, Zlatkov V, Kostova P, Panayotova Y, Holub J, Pavlou P, Papageorgiou C, Von Euler M, Veerus P, Sankila R, Anttila A, Holli K, Grosclaude P, Danzon A, Tzala L, Kamposioras KV, Ferentinos G, Mauri D., et al). Tumori. 2010 Jul-Aug;96(4):524-8.

  106. Evaluating  novel agents effects in multiple-treatments meta-regression. Salanti G, Dias S, Welton NJ, Ades A, GolfinopoulosV, Kyrgiou M, Mauri D., Ioannidis JP. Stat Med. Oct 15;29(23):2369-83

  107. Evaluating the strength of potential misplaced priorities in opportunistic cancer screening practice in Greece. Karampoiki V, Alevizaki P, Lakiotis V, Loukidou E, Terzoudi A, Gkinosati A, Panou C, Ioakeimidou A, Kamposioras K, Valachis A, Tsali L, Pantazi E, Koukourakis G, Karathanasi I, Thanopoulou E, Mauri D. J BUON. 2010 Jan-Mar;15(1):164-73

  108. Partial breast irradiation or whole breast radiotherapy for early breast cancer: a metanalysis of randomized controlled trials. Valachis A, Mauri D., Polyzos NP, Georgoulias V, Mavroudis D, Casazza M.  Breast J. 2010 May-Jun;16(3):245-51. Epub 2010 Feb 23.

  109. Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials. Mauri D., ValachisA, Polyzos N.P, Tsali L, Mavroudis D, Georgoulias V, Casazza G. J Natl Compr Canc Netw. 2010 Mar;8(3):279-86.

  110. Vaginal progesterone gel for luteal phase support in IVF/ICSI cycles: a meta-analysis. Polyzos NP, Messini CI, Papanikolaou EG, Mauri D., Tzioras S, Badawy A, Messinis IEFertil Steril. 2010 Nov;94(6):2083-7. Epub 2010 Feb 19

  111. Intraperitoneal dissemination of endometrial cancer cells following hysteroscopy. A systematic review and meta-analysis. Polyzos NP, Mauri D., Tzioras S, Messini C, Antonis V, Messinis IE. Int J Gynecol Cancer 2010  Feb;20(2):261-7. Review

  112. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D. Breast Cancer Res Treat.2010 Jul;122(1):1-7. Epub 2010

  113. Lack of evidence for fracture prevention in early breast cancer biphosphonates trials: a meta-analysis. Valachis A, Polyzos N.P, Georgoulias V, Mavroudis D, Mauri D. Gynecologic Oncology 2010 Apr;117(1):139-45. Epub 2010 Jan 12. Review.

  114. Port central venous catheters associated bloodstream infection during outpatient-based chemotherapy. Mauri D., Roumbkou S, Michalopoulou S, Tsali L,Spiliopoulou A,Panou C, Valachis A, Panagopoulos A, Polyzos NP. Med Oncol. 2010 Dec;27(4):1309-13.

  115. Partial breast irradiation as an alternative to whole breast radiation. Valachis A, Mauri D.. Eur Oncol. 2010;:2-5

  116. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: a metanalysis.Mauri D., Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, Georgiou C,  Polyzos NP. Cancer Treat Rev. 2010 Feb;36(1):69-74.

  117. Aromatase inhibitors for female infertility: a systematic review of the literature. Polyzos NP, Tzioras S, Badawy AM, Valachis A, Dritsas C, Mauri D.  Reproductive Bio Medicine Online 2009 Oct;19(4):456-71.

  118. Antidepressant Drugs in Cancer Patients: The Case of Escitalopram. Tsali L, Mauri D., Bristianou M, Valachis A, Barotsis N, Bellou E. J Support Oncol. 2009July;7(4):119

  119. Double versus single intrauterine insemination for unexplained infertility. A meta-analysis of randomized trials. Polyzos NP, Tzioras S, Mauri D., Tatsioni A. FertilSteril.2010 Sep;94(4):1261-6.

  120. Combined Vitamin C and E supplementation for Preeclampsia: No Significant Effect But Significant Heterogeneity? Polyzos N, Tzioras S, Mauri D. Hypertension in Pregnancy 2010 :1-2 (doi:10.3109/10641955.2010.507852)

  121. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metanalysis. Mauri D., Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Breast Cancer Res Treat. 2009, June 12;116:433-439

  122. Results of a five split-field technique ofpostoperative 3d radiation therapy in patients with gastric adenocarcinoma. Koukourakis G, Kouloulias V, Platoni K, Koukourakis M, Maravelis G, Fotineas A, Zacharias G, Kamposioras K, Mauri D., Kelekis N. Cancer Therapy 2009; 7:373-377

  123. Screening practice and misplaced priorities. Mauri D., Valachis A, Polyzos NP, Cortinovis I, Karampoiki V, Loukidou E, Alevizaki P, Kamposioras K, Kouris G, Alexandropoulou P, Tsali L, Panou C, Stamatelopoulos A, Lakiotis V, Spiliopoulou A, Terzoudi A, Ioakimidou A, Karathanasi I, Bristianou M, Casazza G, Pavlidis N.  Clin Transl Oncol. 2009 Apr;11(4):228-36

  124. Fulvestrant in the treatment of advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials. Valachis A, Mauri D., Polyzos NP, Mavroudis D, Georgoulias V, Casazza G. Crit Rev Oncol Hematol. 2010 Mar;73(3):220-7. Epub 2009 Apr 14.

  125. Tyrosine kinase inhibitors in treatment of fibroushistiocytoma. Mauri D., Panou C, Valachis A, Kamposioras K, Tsali L. Exp Oncol. 2009 Mar;31(1):60-1.

  126. Effect of periodontal disease treatment during pregnancy on preterm birth incidence. A meta-analysis of randomized trials. Polyzos NP, Polyzos IP, Mauri D.,Tzioras S,  Tsappi M, Cortinovis I, Casazza G. Am J Obstet Gynecol 2009Mar;200(3):225-32.

  127. Time-Trend of Melanoma Screening Practice  by Primary Care Physicians: a Meta-Regression Analysis. Valachis A, Mauri D., Karampoiki V, Polyzos NP, Cortinovis I, Koukourakis G,  Zacharias G, Xilomenos A, Tsappi M, Casazza G. Uppsala J Med Sci 2009;114(1):32-40.

  128. Double–blind control of the data manager doesn't have any impact on data entry reliability and should be considered as an avoidable cost. Mauri D., Karampoiki V, Mauri J, Kamposioras K, Alexiou G, Ferentinos G, Tsali L, et al. BMC Medical Research Methodology 2008, 8:66 (20 October 2008)

  129. Moving ahead in diabetics' cancer screening; food for thought from the Hellenic experience. Karathanasi I, KamposiorasK,Cortinovis I, Karampoiki V, AlevizakiP, Dambrosio M, Zorba E, Panou C, Pantazi E, Bristianou M,  Kouiroukidou P, Bouiatiotis E, Xilomenos A, Zavou D, Casazza G, Mauri D. Eur J Cancer Care 2009 May;18(3):255-63

  130. Multiple treatments meta-analysis of chemotherapy andtargeted therapies in advanced breast cancer.  Mauri D., Polyzos NP, Salanti G, Pavlidis N, Ioannidis JP. J Natl Cancer Inst. 2008 Dec 17;100(24):1780-91. Epub 2008 Dec 9.

  131. Letrozole in ovulation induction. Time to make decisions. Polyzos NP, Tzioras S, Mauri D. Hum Reprod Update 2008  Mar-Apr;15(2):263-4. Epub 2008 Nov 5.

  132. Cancer screening in Greece. Guideline awareness and  prescription behavior among Hellenic physicians. Kamposioras K, Mauri D., AlevizakiP, Ferentinos G, Karampoiki V, Kouiroukidou P, Zorba E, Proiskos A, Chasioti D, Panou C, Gkinosati A, Chatziioannou I, Aggelinas G, Xilomenos A. Eur J Int Med. 2008; 19:452-460.

  133. Medical alert:  Weekly docetaxel regimens & Radiation pneumonitis. Mauri D., Tzachanis D, Tsekoura P, Xanthakis I, TsaliL, Roumbkou S, Funtzilas G. J Support Oncol. 2008Jul-Aug; 6(6):265-6.

  134. Treatment of unexplained infertility with aromatase inhibitors or clomiphene citrate: A systematic review and meta-analysis. Polyzos NP, Tzioras S, Mauri D., Tsappi M, Cortinovis I, Tsali L, Casazza G. Obstet Gynecol Surv. 2008 Jul;63(7):472-9

  135. Responsibilities in cancer preventive care in Greece. A physicians’ survey Zacharias G, Xilomenos A, Koukourakis G, Kamposioras K, Mauri D., Chasioti D, Bristianou M, Ferentinos G, Levantakis I, Tsali L, Valachis A, Karampoiki V..Clin Transl Oncol. 2008 Apr;10(4):231-4

  136. Low colorectal cancer screening rates and primary care physicians’ behaviour. Kamposioras K, Mauri D., Tsali L, Valachis A, Polyzos NP.  Am J Gastroenterol 2008 Mar;103(3):804-5.

  137. Aromatase inhibitors for infertility in the polycystic ovary syndrome. The beginning or the end of a new era? Polyzos NP, Tsappi M, Mauri D., Atay V, Cortinovis I, Casazza G. FertilSteril. 2008 Feb;89(2):278-280.

  138. Effects of quadrivalent human papaillomavirus vaccination. Mauri D., Polyzos NP. Lancet, 2007 Sept 22;370:1031

  139. SESy_Europe met skin  cancer screening. Karampoiki V, Rivas Flores F.J., Altinoz H, Chojnacka M, Karentzou I, Dambrosio M,     Colichi  C,  Oxiuzova  T,  Kanavoura  E,  Maia da Silva Alves de Sousa B.A., Ivanova D,  Alexiou G, Mauri D. Cent Eur J Public Health 2007 Jun;15(2):71-3

  140. Response: Survival With Aromatase Inhibitors and Inactivators Versus Standard Hormonal Therapy in Advanced Breast Cancer: Meta-analysis. Ioannidis JP, Mauri D., Polyzos NP, Pavlidis N. J Natl Cancer Inst. 2007 Jan 17;99(2):176-7.

  141. RE: Impact of chest radiography screening on healthcare spending. Kamposioras K, Mauri D., Tsekoura P, Valachis A, Tsappi M, Polyzos N. Am J Manag Care. 2007 Apr;13(4):218-9.

  142. Combined vitamin C and E supplementation during pregnancy for preeclampsia prevention: a systematic review. Polyzos NP, Mauri D., Tsappi M, Tzioras S, Kamposioras K, Cortinovis I, Casazza G Obstet Gynecol Surv. 2007 Mar;62(3):202-6

  143. Socio-demographic status and alcohol drinking patterns among Greek healthy adults. Pazarlis P, Mauri D.,Cortinovis I, Katsigiannopoulos K, Alevizaki P, Koukourakis G, Casazza G, Kamposioras K, Chatziioannou I, Milousis A, Papakonstantinou A, Karathanasi I, Alexiou G, Proiskos A, Mitrogianni Z, Peponi C..CentEur J Public Health. 2006 Dec; 14(4):160-7.

  144. Tumor marker prescriptions for cancer screening in the Hellenic primary care. Vittoraki A, Alexiou G, Karakatsanis A, Mauri D., Xilomenos A, Zacharias G, Koukourakis G, Hrysovalantou-Marsoni Ei, Milousis A, Athanasiadou M, Chasioti D.  Eur J Cancer Care (Engl.) 2007 Jan;16(1):86-9.

  145. Rethinking anticancer screening strategies saving lives at front line. Results from SESy_Europe task force. Mauri D., Kamposioras K, Polyzos NP, Rivas Flores FJ, Altinoz H, Chojnacka M, Karentzou I, Dambrosio M, Colichi C, Oxiuzova T, Kanavoura E, da Silva Alves de Sousa BA, Ivanova D, Mauri J, Karampoiki V, Maragkaki A, Xilomenos A. Exp Oncol. 2006 Sep;28(3):252-3l  

  146. Old habits die hard: chest radiography for screening purposes in primary care. Mauri D., Kamposioras K, Proiskos A, Xilomenos A, Peponi C, Dambrosio M, Zacharias G, Koukourakis G, Pentheroudakis G, Pavlidis N. Am J Manag Care. 2006 Nov;12(11):650-6

  147. Food for Thought in Women’s Health. Gynecologist: New European Gate-keeper in Chlamydia Trachomatis Infection. Polyzos NP, VittorakiA,  Tsappi M, Mauri D., Spiliopoulou A, Tzioras S, KamposiorasK, IoakeimidouA. Acta Obstet Gynecol Scand. 2006;85(10):1156-9

  148. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. Mauri D., Pavlidis N, Polyzos NP, Ioannidis JP. J Natl Cancer Inst. 2006 Sep 20;98(18):1285-91.

  149. Colorectal cancer screening coverage in Greece. Kamposioras K, Mauri D., Golfinopoulos V, Ferentinos G, Zacharias G, Xilomenos A, Polyzos NP, Bristianou M, Chasioti D, Milousis A, Vittoraki A, Koukourakis G, Chatziioannou I, Papadopoulos P. PACMeR 02.01 study collaboration. Int J Colorect Dis 2007;22:475-81.

  150. Non-small Cell Lung Cancer in the Young: A Retrospective Analysis of Diagnosis, Management and Outcome Data. Mauri D., Pentheroudakis G,  Bafaloukos D. Pectasides D, Samantas E, Efstathiou E, Kalofonos HP, Syrigos K, Klouvas G, Papakostas P, Kosmidis P, Fountzilas G, Pavlidis N; Hellenic Coopeprative Oncologic Group (HeCOG). Anticancer Res. 2006 Jul-Aug;26(4B):3175-81.

  151. “Juvenile” oncology - a missing subspecialty. Food for thought from the experience of a reference cancer centre. G. Pentheroudakis, D. Mauri, L. Kostadima, V. Golfinopoulos, G. Alexiou, A. Karacatsanis, N. Pavlidis. Clin Transl Oncol 2006 Jun;8(6):444-9

  152. Colorectal cancer screening awareness among physicians in Greece. Xilomenos A, Mauri D., Kamposioras K, Gkinosati A, Zacharias G, Sidiropoulou V, Papadopoulos P, Chatzimichalis G, Golfinopoulos V, Peponi C, Pacmer PA. BMC Gastroenterol. 2006 Jun 6;6(1):18

  153. Screening Chest Radiography: Results from a Greek Cross-Sectional Survey. Kamposiora K, Casazza G, Davide Mauri, Velisarios Lakiotis V, Cortinovis I, Xilomenos A, Peponi C, Golfinopoulos V, Milousis A, Kakaridis D, Zacharias G, Karathanasi I, Ferentinos G, Proiskos A.BMC Public Health, 2006 Apr 29;6(1):113

  154. Colorectal cancer screening awareness in European Primary Care. Mauri D., Pentheroudakis G, Milousis A, Xilomenos A, Panagoulopoulou E, Bristianou M, Zacharias G, Christidis D, Mustou EA, Gkinosati A, Pavlidis N. Cancer Detect Prev 2006;30(1):75-82

  155. Screening chest radiography in Primary Care: an underestimated belief. Proiskos A, Loukidou E, Kamposiora K, Bristianou M, Zina V, Pliadi O, Karakatsanis A, Alexiou G, Gkougkoutsi A, Mauri D. Eur J Gen Pract 2005/11(2):76-77.

  156. Is Primidone the drug of choice for epileptic patients with QT prolongation? A comprehensive analysis of literature. Christidis D, Kalogerakis D, Chan TY, Mauri D., Alexiou G, Terzoudi E. Seizure – Eur J Epilep 2006 Jan;15(1):64-6. Epub 2005 Nov 22

  157. Inflammatory prostate cancer: An underestimated paraneoplastic clinical manifestation. Mauri D., Pentheroudakis G, Tolis C, Chojnacka M, Pavlidis N. Urol Oncol 2005 /23(5):318-22

  158. Chlamydia trachomatis: time for screening? Spiliopoulou A, Lakiotis V, Vittoraki A, ZavouD, Mauri D. Clin Microbiol Infec 2005/11(9):687-9.

  159. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes. Pentheroudakis G, Briasoulis E, Karavasilis V, Mauri D., Tzamakou E, Rammou D, Pavlidis N. Chemotherapy. 2005/51(2-3)/154-61.

  160. Re:Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis – Response Mauri D., Pavlidis N, Ioannidis JPA. J Nat Cancer Inst  2005/97(11):858-859

  161. Neoadjuvant versus adjuvant systemic treatment in breast cancer : a meta-analysis. Mauri D., Pavlidis N, Ioannidis JPA.  J Nat Cancer Inst  2005/97(3)/188-94.

  162. Health economics: is smoking a trigger point for screening chest radiography opportunistic practice? Karakatsanis A, Alexiou G, Kalogerakis D, Mauri D. CMAJ-e 2004

  163. Sesy Europe: a multi-language database dedicated to cancer screening monitoring. Mauri D., Pazarlis P, Mauri J, Altinoz H, Rivas Flores FJ, Karentzou I., et al.  J Exp Clin Cancer Res 2004; 23(3):207-211

  164. Urinary test use for cancer screening: an underestimated health economics pitfall? Panou C, Alevizaki P, Mauri D., Ioakimidou A, Vittoraki A, Spiliopoulou A, Chasioti D, Loukidou E, Kouris G, Pentheroudakis G. J Lab Clin Med. 2004 Jun;143(6):366-7.

  165. PC 3-component database for community-based medical trials. A cost-effective solution both for voluntary associations and for institutions of the “Emerging World”. Mauri J, Mauri D., Pazarlis P, Altinoz H, Rivas Flores FJ, Karentzou I., et al. Gazz Med It – Rev Sci Med 2004/163(5)/189-194

  166. QT length and heart function in primidone hypocalcaemia. Loukeris K, Mauri D., Pazarlis P. Acta Cardiol. 2002 Oct;57(5):367-9.

  167. Hyperpyrexia secondary to acute hypocalcemic status. Is there a role for calcitonin therapy in bone metabolism derangements due to anticonvulsant drugs? Alexandropoulou P, Mauri D., Rigatou E, Karampoiki V. Minerva Med. 2000; 91:321-3

  168. Plasma mitomycin C concentrations determined by HPLC coupled to solid-phase extraction. Paroni R, Arcelloni C, De Vecchi E, Fermo I, Mauri D., Colombo R. Clin Chem. 1997 Apr;43(4):615-8.

ΚΑΡΤΑ 1.jpg

ΣΥΓΓΡΑΦΗ ΚΕΦΑΛΑΙΩΝ ΣΕ ΙΑΤΡΙΚΑ ΒΙΒΛΙΑ ΚΑΙ ΕΚΔΟΣΕΙΣ

  1. Central Venous Catheter Infection Outbreaks in Clinical Practice: Investigation and Management.Davide Mauri et all. Book numbered series: Advances in Medicine and Biology. Volume 142. Nova Science Publishers, Inc. 400 Oser Avenue, Suite 1600 Hauppauge, NY 11788 US

  2. Central Venous Catheters (CVCs) Early Dysfunction and Misplacement. Davide Mauri et al. Book numbered series: Advances in Medicine and Biology.Volume 142. Nova Science Publishers, Inc. 400 Oser Avenue, Suite 1600 Hauppauge, NY 11788 US​

  3. Carcinoid tumors and Syndrome. Mauri D. ACP Pier Module (American College of Physicians PIER Physicians’ Information and Education Resource)ACP PIER ON-LINE 15.11.2011-15.11.2014 http://pier.acponline.org​

  4. Carcinoid tumors and Syndrome.Kim MK, Patel KK. (Mauri D.  Editorial Consultant for module update)ACP Pier Module (American College of Physicians PIER Physicians’ Information and Education Resource) ACP PIER ON-LINE update 2008.

  5. Carcinoid tumors and Syndrome.Kim MK, Patel KK. (Mauri D.  Editorial Consultant for module update)ACP Pier Module. (American College of Physicians PIER Physicians’ Information and Education Resource) ACP PIER ON-LINE update 2010. 

  6. “European vs. North American cancer screening attitude and practices in primary care. A systematic review and a critical appraisal for the implementation of evidence based and non evidence based tests”.in “Health Knowledge, Attitudes, and Practices.”Mauri D., Kamposioras K, Valachis A, Polyzos NP, et al.. Novapublishers, New York. Editor: Frank Columbus.                      “Aromatase Inhibitors in Ovulation Induction: Myth or Reality?”in “Aromatase Inhibitors: Types, Mode of Action and Indications”Nikolaos P. Polyzos, Spyridon Tzioras, Davide Mauri, et al. Nova publishers, New York. Editor: Jean R. Lamonte

  7. The Action – Final scientific report 31/3/2008. EUROCHIP-II (European Cancer Health Indicator Project –II) – (European Commission, Directorate C, Public health Assessment Health and Consumer Protection Directorate general - granted program) see EUROCHIP-2 working Group, pg 2.​

  8. Information on cancerMicheli A, Baili P. - Chapter 9 –in Responding to the challenge of cancer in Europe. Edited by Coleman MP, Alexe D-M,  Albreht T, McKee M. Institute of Public Health of the Republic of Slovenia, 2008, Ljiubljana – funded by the European Union in the framework of the Public Health Programme - pg177- 189. Mauri Davide, pg.188 in the EUROCHIP-2 working Group.http://www.euro.who.int/Document/E91137.pdf (open-access book, last time accessed 20 February 2008

  9. Cancer Baili P, Casella I, Amati C, Micheli A, and EUROCHIP Working Group. - Chapter 5 –in Major and Chronic Disease (MCD) Report 2007, Printed in Luxemburg by the service of the European Commission page 66-88

  10. Ipospadia in Corso di Chirurgia ricostruttiva dell’ uretra Traverso P, Simonato A, De Rose AF, Galli S, Mauri D., Carmignani G:  “LIVE” Ed. Universita’ degli studi di Genova 7-9 Ottobre 1996: 13-17

  11. Epispadia in Corso di Chirurgia ricostruttiva dell’ uretra Mauri D., Simonato A, De Rose AF, Traverso P, Galli S, Carmignani G:  “LIVE” Ed. Universita’ degli studi di Genova 7-9 Ottobre 1996: 18-24

  12. Le valvole uretrali in Corso di Chirurgia ricostruttiva dell’ uretra Galli S, Simonato A, Mauri D., De Rose AF, Traverso P, Carmignani G  “LIVE” Ed. Universita’ degli studi di Genova 7-9 Ottobre 1996: 25-33

  13. Le ricostruzioni complesse dell’ uretra in tempo unico: l’ uso dei lembi liberi in Corso di Chirurgia ricostruttiva dell’ uretra. Carmignani G, Simonato A, Traverso P, Galli S, Mauri D., De Rose AF. “LIVE” Ed. Universita’ degli studi di Genova 7-9 Ottobre 1996: 57-61. ΔΥΣΧΕΡΗΣ ΦΛΕΒΟΚΑΘΕΤΗΡΙΑΣΜΟΣ ΣΕ ΑΣΘΕΝΕΙΣ ΧΩΡΙΣ ΑΙΜΟΡΡΑΓΙΑ

  14. D.Mauri, Β. Καραμποίκη, Π. Αλεξανδροπούλου, Ε. Ρηγάτου, Β.Λακιώτης, Α. Αρτέμη, Ε. Οικονόμου, Χ. Δεμπονερας, Α. Γιαννακα, Γ. Κουρης. Εξέλιξη στην χειρουργική, 2000

© 2026 Dr Mauri Davide- Δρ Μάουρι Ντάβιντε-Ογκολόγος- Επ. Καθηγητής Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκη

Επιστροφή στην αρχή

bottom of page